Group 1 - The company *ST Asia Pacific (000691.SZ) expects a net loss of between 51.46 million to 28.39 million yuan for 2025, with a non-recurring net loss projected between 43.95 million to 24.25 million yuan, and operating revenue estimated to be between 416.80 million to 599.15 million yuan [1] - The increase in operating revenue and net profit compared to the same period last year is primarily attributed to the recovery of the industry cycle and the rebound in demand for pesticides and pharmaceutical intermediates [1] - The equity attributable to shareholders of the listed company has significantly increased compared to the same period last year, mainly due to the completion of bankruptcy reorganization, receipt of reorganization investment funds, debt exemptions, and cash donations [1]

【利民股份：2025年净利润同比预增471.55%-514.57%】智通财经1月21日电，利民股份(002734.SZ)发 布业绩预告，预计2025年归母净利润为4.65亿元-5亿元，同比增长471.55%-514.57%。公司净利同比增 长的主要原因是公司主要产品销量和价格同比上涨、毛利率提升以及参股公司业绩上涨带来投资收益增 加。 转自：智通财经 ...

Core Viewpoint - The performance of Runfeng Co., Ltd. has significantly improved, necessitating a reassessment of the value of its formulation exports, with expected net profit attributable to shareholders projected at 1.03-1.17 billion yuan, representing a year-on-year increase of 129% to 160% [1] Financial Performance - The company anticipates a net profit of 140-280 million yuan for Q4 2025, reflecting a year-on-year growth of 9% to 119%, but a quarter-on-quarter decline of 62% to 25% [1] - The overall performance for 2025 is expected to show substantial improvement due to the gradual recovery of procurement demand and the bottoming out of product prices [1] Market Outlook - Looking ahead to 2026, the demand for pesticides and product prices are expected to improve further compared to 2025, particularly with seasonal orders likely to exceed expectations, driving accelerated recovery in market conditions [1] - As a leading domestic exporter of formulations, the company is continuously enhancing its global marketing network, which will strengthen its profitability as the ModelC business matures and its market share increases [1] Strategic Positioning - The company is well-positioned to expand into high-barrier, high-value markets such as North America and the European Union, which will contribute to sustained improvements in profitability [1] - The industry is experiencing a steady recovery in market conditions, with ongoing strategic planning and continuous improvement in operational quality [1]

Core Viewpoint - *ST Asia Pacific has released its annual performance forecast, indicating a significant fluctuation in revenue and net profit for 2025, primarily due to industry recovery and restructuring efforts [1] Group 1: Financial Performance - The expected total revenue for 2025 is projected to be between 417 million and 599 million yuan [1] - The net profit attributable to shareholders is forecasted to range from -51.4581 million to -28.3907 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -43.9538 million and -24.2504 million yuan [1] Group 2: Reasons for Performance Changes - The increase in revenue and net profit compared to the previous year is mainly attributed to the recovery of the industry cycle and the rebound in demand for pesticides and pharmaceutical intermediates [1] - The significant growth in shareholders' equity compared to the previous year is primarily due to the completion of bankruptcy reorganization, receipt of reorganization investment funds, debt exemptions, and cash donations [1]

利民股份公告，预计2025年度归属于上市公司股东的净利润为盈利4.65亿元-5亿元，比上年同期增长 471.55%-514.57%。预计扣除非经常性损益后的净利润为盈利4.43亿元-4.8亿元，比上年同期增长 765.53%-837.82%。主要原因是：公司主要产品销量和价格同比上涨、毛利率提升以及参股公司业绩上 涨带来投资收益增加。 ...

Group 1: Company Performance Forecast - The company expects to achieve revenue of 145.5-147.5 billion yuan in 2025, representing a year-over-year increase of 9% to 11% [1] - The forecasted net profit attributable to shareholders is projected to be 10.3-11.7 billion yuan, reflecting a significant year-over-year increase of 129% to 160% [1] - For Q4 2025, the company anticipates revenue of 36.4-38.4 billion yuan, with a year-over-year growth of 4% to 9% [1] Group 2: Market Conditions and Product Pricing - In 2025, the global pesticide market is experiencing a recovery in procurement demand, with many product prices reaching a bottom [2] - The pesticide raw material price index reported by Zhongnong Lihua was 71.44 as of December 28, 2025, down 2.1% from the end of 2024 [2] - The company is focusing on rapid growth in its To C business, with an increase in the proportion of insecticide and fungicide sales, leading to improved operational quality and gross margins [2] Group 3: Export and Regulatory Environment - Starting April 1, 2026, the government will cancel VAT refunds on certain pesticide raw materials, which may lead to a "rush to export" before this date [3] - The cancellation of export tax rebates is expected to accelerate the elimination of outdated raw material production capacity while benefiting the export of pesticide formulations [3] - The company is enhancing its global marketing network and is well-positioned to strengthen its profitability as it expands into high-value markets like North America and the EU [3] Group 4: Investment Outlook - The company maintains its net profit forecasts for 2025-2027 at 11.48, 13.97, and 16.90 billion yuan, with corresponding P/E ratios of 19, 16, and 13 times [3] - The industry is expected to gradually recover, and the company's strategic planning and operational quality improvements support a "buy" rating [3]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to achieve revenue of 145.5-147.5 billion yuan for 2025, representing a year-over-year growth of 9% to 11%. The net profit attributable to shareholders is projected to be between 10.3-11.7 billion yuan, indicating a significant year-over-year increase of 129% to 160% [4] - The company has seen a recovery in procurement demand since 2025, with most product prices reaching a bottom. The global pesticide market is gradually normalizing, leading to substantial improvements in the company's performance [6] - The company is enhancing its global marketing network, and the value of its overseas formulation business needs to be reassessed. The cancellation of certain export VAT rebates is expected to create a "rush to export" scenario before April 1, 2026, which may boost demand for various products [6] Financial Data and Profit Forecast - The total revenue for 2025 is estimated at 14,645 million yuan, with a year-over-year growth rate of 10.1%. The net profit attributable to shareholders is forecasted to be 1,148 million yuan, reflecting a year-over-year growth of 155.1% [5] - The company’s gross margin is expected to improve, with projections of 21.9% for 2025 and 22.6% for 2026. The return on equity (ROE) is anticipated to be 14.8% in 2025 and 15.8% in 2026 [5] - The current market capitalization corresponds to a price-to-earnings (PE) ratio of 19 for 2025, 16 for 2026, and 13 for 2027, indicating a favorable valuation as the industry recovers [6]

旺季刺激+抢出口，草铵膦、草甘膦价格上涨 事件：#草甘膦、草铵膦价格上调。 1月9日财政部和国家税务总局宣布自2026年4月1日起，部分农药及原药中间体等产品增值税出口退税率取消/下 调。 1月16日草铵膦提价至46000元/吨，较前日上调2100元/吨；1月19日草甘膦提价至23296元/吨，较前日上调200元/ 吨。 1、#2010年草甘膦退税取消加速行 旺季刺激+抢出口，草铵膦、草甘膦价格上涨 事件：#草甘膦、草铵膦价格上调。 1月9日财政部和国家税务总局宣布自2026年4月1日起，部分农药及原药中间体等产品增值税出口退税率取消/下 调。 1月16日草铵膦提价至46000元/吨，较前日上调2100元/吨；1月19日草甘膦提价至23296元/吨，较前日上调200元/ 吨。 1、#2010年草甘膦退税取消加速行业出清。 回溯此前，2010年7月草甘膦出口退税率取消，叠加2010年草甘膦价格低至19600元/吨震荡，处于行业成本线之下 运行，与此同时国内加紧环保核查，草甘膦供给端出清加速，最终草甘膦周期启动，价格涨至45000元/吨。 2、#草铵膦格局有望大幅优化。 草铵膦格局和2010年的草甘膦类似，根据百 ...

Group 1: Company Performance Overview - The company did not meet its sales revenue budget for 2025 due to the cancellation of significant contracts in Brazil and Argentina, influenced by rising credit risks [5][6] - The gross margin for Q4 2025 exceeded 25%, marking the highest quarterly gross margin in the past decade, with an annual increase of over 3 percentage points compared to 2024 [5][8] - The total expenses as a percentage of sales slightly decreased compared to 2024, ending the upward trend seen in the previous two years [5][10] Group 2: Market Risks and Projections - Credit risks in Brazil and Argentina are expected to remain high in 2026, potentially impacting sales revenue growth [6][7] - The company anticipates a higher sales revenue growth rate in 2026 compared to 2025, driven by new product registrations and team expansions in Brazil [7][8] - The company aims to maintain a gross margin higher than 2025 due to strategic planning and product registration efforts [10][11] Group 3: Financial Management and Cost Control - The company plans to keep the total expense ratio stable while reducing management expenses and increasing sales and R&D expenses [10][11] - Asset impairment provisions for 2024 and 2025 are estimated at approximately 200 million, reflecting challenges in accounts receivable risk management [13][14] - The company aims to reduce asset impairment provisions to below 0.5% by the end of 2029 [13][14] Group 4: International Trade and Product Pricing - China's agricultural pesticide exports remain strong, attributed to the competitive pricing of Chinese products, with no significant inventory buildup reported globally [15][16] - The cancellation of export tax rebates for certain raw pesticide products is expected to benefit the export of finished pesticide formulations [15][16] - Current raw pesticide prices are at historical lows, with uncertain timing for potential price rebounds [15][16] Group 5: Operational Developments - The U.S. manufacturing facilities are operating at full capacity, supporting business growth in the region [18][19] - The company plans to establish a new processing facility in the U.S. by 2027 to enhance production capabilities [18][19]

Group 1 - The core viewpoint of the article is that Noposion (002215) is making significant strides in its overseas expansion with the establishment of a base in Laos, which is a crucial step for the company [1] - The first phase of the base has been completed, indicating progress in the company's international operations [1] - The expected contribution to production from this base is projected for the 2026-2027 production season, highlighting the long-term planning and investment strategy of the company [1]